News

Zacks Investment Research on MSN1d
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...
Medscape1d
Digital Tech for Schizophrenia on the Brink of a Breakthrough?
Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...
Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data
Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...
J&J defeats generic drugmakers in US appeal over schizophrenia treatment
Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...
'Dimmer switch' drug candidates offer hope for safer nerve pain and ischemic disease treatments
Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...
Fierce Pharma4d
Regulatory tracker: With FDA filing, J&J targets Caplyta expansion into schizophrenia relapse prevention
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...